{
    "title": "FY2024 Earnings Estimate for Capricor Therapeutics Inc (NASDAQ:CAPR) Issued \nBy Cantor Fitzgerald",
    "date": "3/18/2024",
    "url": "https://www.marketbeat.com/instant-alerts/nasdaq-capr-analyst-earnings-estimates-2024-03-18/",
    "text": "Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Capricor Therapeutics in a report issued on Wednesday, March 13th. Cantor Fitzgerald analyst K. Kluska expects that the biotechnology company will post earnings of ($0.84) per share for the year. Cantor Fitzgerald has a \"Overweight\" rating and a $8.00 price target on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($0.83) per share. Other research analysts have also recently issued reports about the company. HC Wainwright restated a \"buy\" rating and set a $40.00 target price on shares of Capricor Therapeutics in a report on Friday, March 1st. StockNews.com upgraded Capricor Therapeutics from a \"sell\" rating to a \"hold\" rating in a report on Wednesday, January 24th. Get Our Latest Report on CAPR CAPR stock traded up $0.37 during trading on Monday, hitting $6.76. The stock had a trading volume of 527,066 shares, compared to its average volume of 246,650. The company's 50-day moving average price is $4.44 and its two-hundred day moving average price is $4.17. Capricor Therapeutics has a twelve month low of $2.68 and a twelve month high of $8.22.  Institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its position in shares of Capricor Therapeutics by 138.7% during the 1st quarter. Tower Research Capital LLC TRC now owns 8,770 shares of the biotechnology company's stock valued at $37,000 after buying an additional 5,096 shares during the period. Charles Schwab Investment Management Inc. purchased a new stake in shares of Capricor Therapeutics during the 1st quarter valued at approximately $51,000. Renaissance Technologies LLC purchased a new stake in shares of Capricor Therapeutics during the 3rd quarter valued at approximately $61,000. HighTower Advisors LLC raised its position in Capricor Therapeutics by 17.8% in the fourth quarter. HighTower Advisors LLC now owns 19,885 shares of the biotechnology company's stock valued at $76,000 after purchasing an additional 3,001 shares during the period. Finally, UBS Group AG raised its position in Capricor Therapeutics by 326.0% in the second quarter. UBS Group AG now owns 29,352 shares of the biotechnology company's stock valued at $102,000 after purchasing an additional 22,462 shares during the period. Hedge funds and other institutional investors own 10.18% of the company's stock. Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor\u2019s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.Featured ArticlesFive stocks we like better than Capricor TherapeuticsElection Stocks: How Elections Affect the Stock MarketWalmart: Here\u2019s Your Chance to Get in Cheaper in 2024Russell 2000 Index, How Investors Use it For Profitable TradingInsider Selling of Amazon Spikes in Q1, but it's Not Time to SellConsumer Staples Stocks, Explained2 Deep Value, High Yield Stocks With a Double-Digit Upside Before you consider Capricor Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list. While Capricor Therapeutics currently has a \"Buy\" rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. As Featured By: 345 N Reid Place, Suite 620, Sioux Falls, SD 57103\n\ncontact@marketbeat.com\n\n(844) 978-6257 \u00a9 MarketBeat Media, LLC\u00ae 2010-2024. All rights reserved. \u00a9 2024 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer. My Account - "
}